PAA

0.00%

17.5¢ pharmaust limited

Thank you for all the effort in sharing that PickEm. I'm gonna...

First 13 Last

Share
Profile

Follow
illdrink2that

1,402 Posts.

987

05/07/20

16:03

Post #: 45653374
Share

Originally posted by PickEm: ↑

Adaptive Cell Therapy

When viewed in relation to targeted cancer drugs, part of the idea is that you're not pushing cancer so hard that it evolves quickly past the block you've put in.

Professor Maley is saying that as cancer evolves within a lifetime, to maximise the active longevity of patients, the dose and timing of treatments must be guided by evolutionary principles - which we understand fairly well. Even the immune system doesn't try to completely eradicate invaders, but to knock them down to harmless levels. It's a cost benefit balance.

The Moffitt Cancer Centre in the US ran an adaptive therapies metastatic prostate trial which is now complete and being written-up. The released results will not disappoint because the interim results were so spectacular. The 3 other trials are underway; ovarian, melanoma and thyroid. The Moffitt Cancer Centre is a rather special place and I get the feeling of restrained excitement from them.

There is the possibility that monepantel is ideally suited to this approach - close to non-toxic at lower doses, sometimes tumour reducing but more tumour holding over time. A dramatic reduction in tumour size is currently considered a good thing, but adaptive therapy says no. Just holding tumour growth will be far more beneficial to extending long term survival.

And then monepantels latest gift which has gone largely unnoticed.Monepantel has a biphasic nature which might be dose forgiving. If efficacy is assumed to be its tumour reducing performance, it gives a "U" with optimal dose efficacy at the bottom of the U. If halting growth is best efficacy, the biphasic "U" turns more into a "W" ... we have possibly dosed slightly high but maybe near enough to the second dip - as hinted by the 4 dogs in 28 day stasis - around a point where adaptive control might work.

I think little PharmAust has a big shot. Can't see any other junior pharma on the ASX playing with such upside, and that ignores the virus. Could be one hell of a ride but all imo.

Either way, the coming weeks are guaranteed to be interesting.
Well that was an effort and hope my fellow holders find some of it interesting. I'm all worded out ... siesta time ...

Good luck to all holders ... and just for Cashie .. !sredloh lla ot kcul dooG

Expand

Thank you for all the effort in sharing that PickEm. I'm gonna have to go back through all the posts again to get my head around some of those bits though. I'm glad your sentiment is HOLD. I owe you GAs but have run out again for the day. Really excellent posts coming through this weekend!

PAA Price at posting: 24.0¢ Sentiment: Hold Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

There are more pages in this discussion • 28 more messages in this thread...

First 13 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 17.5¢		Change 0.000(0.00%)		Mkt cap ! $85.12M

Open	High	Low	Value	Volume
18.0¢	18.0¢	17.0¢	$141.2K	801.7K

Buyers (Bids)

No.	Vol.	Price($)
11	537419	17.0¢

Sellers (Offers)

Price($)	Vol.	No.
18.0¢	140000	3

View Market Depth

No.	Vol.	Price($)
11	537419	0.170
5	157060	0.165
9	476304	0.160
6	336734	0.155
8	225333	0.150

Price($)	Vol.	No.
0.180	140000	3
0.185	427553	5
0.190	720215	6
0.195	752882	12
0.200	297726	10

Last trade - 16.10pm 06/09/2024 (20 minute delay)

PAA (ASX) Chart

Thank you for all the effort in sharing that PickEm. I'm gonna...

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Shekel Brainweigh investor presentation webinar – the future of retail automation

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you for all the effort in sharing that PickEm. I'm gonna...

Top Stories

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Shekel Brainweigh investor presentation webinar – the future of retail automation

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News